Pediatr. praxi. 2025;26(3):163-165 | DOI: 10.36290/ped.2025.031

Doxycycline - a needless concern for pediatricians?

MUDr. Miroslav Belbl
Dětské a dorostové oddělení, Nemocnice Písek, a. s.

Doxycycline is an antibiotic associated with adverse effects for which it is used with caution, especially in the pediatric population. As has become apparent in recent years, due to the increasing number of cases of pneumonia caused by Mycoplasma pneumoniae, including those with a severe course, it has been and increasingly needs to be considered for therapy in the pediatric population. The increasing resistance of these bacteria to macrolide antibiotics may be a major reason. Fortunately, according to new studies, the new generation of tetracycline antibiotics no longer pose such a risk of tooth and bone damage compared with tetracycline alone. The article discusses the prevalence of mycoplasma resistance to macrolide antibiotics, the possible use of doxycycline even in the youngest children and the indications in which its widespread use would be most appropriate.

Keywords: doxycycline, mycoplasma, antibiotic resistence.

Accepted: June 16, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belbl M. Doxycycline - a needless concern for pediatricians? Pediatr. praxi. 2025;26(3):163-165. doi: 10.36290/ped.2025.031.
Download citation
PDF will be unlocked 4.7.2026

References

  1. . Štefan M. Antibiotika v klinické praxi. Třetí, přepracované a rozšířené vydání. Praha: Galén; 2024.
  2. . Poyhonen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children. J Antimicrob Chemother. 2017;72(10):2887-2890. Go to original source... Go to PubMed...
  3. . American Academy of Pediatrics. Lyme disease. In: Red Book, 31, Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. 2018. p. 515.
  4. . Joshi G, Dhingra D, Pandav SS, et al. Doxycycline-induced staining of teeth and malar rash in a child. J Postgrad Med. 2020;66(1):54. Go to original source... Go to PubMed...
  5. . Adámková V. Antibiotika v primární péči. 2., přepracované a doplněné vydání. Praha: Grada Publishing; 2024.
  6. . Detail varianty léčivého přípravku DOXYBENE [Internet]. Praha: SÚKL; c2025. [cited 2025 Apr 10]. Available from: https://prehledy.sukl.cz/.
  7. . Hurych J, Sticha R, et al. Lékařská mikrobiologie - Repetitorium. 3. vydání. Praha: Triton; 2021.
  8. . Wormser GP, Strle F. Evaluation of the role of oral penicillin for treating Lyme disease patients with erythema migrans in the United States. Diagn Microbiol Infect Dis. 2020; 97(4):115071. Go to original source... Go to PubMed...
  9. . Bremell D, Trollfors B. Doxycycline can be given to children without risk of staining of teeth. Lakartidningen. 2017; 23:114:ERIC.
  10. . Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-76. Go to original source... Go to PubMed...
  11. . Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2024;20(9):901-914. Go to original source... Go to PubMed...
  12. . Kim K, Jung S, Kim M, et al. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2220949. Go to original source... Go to PubMed...
  13. . Waites KB, Ratliff A, Crabb DM, et al. Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program. J Clin Microbiol. 2019;57(11):e00968-19. Go to original source... Go to PubMed...
  14. . Loconsole D, De Robertis AL, Sallustio A, et al. Update on the Epidemiology of Macrolide-Resistant Mycoplasma pneumoniae in Europe: A Systematic Review. Infect Dis Rep. 2021;13(3):811-820. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.